8th Asia Dengue Summit Renews Call to Achieve Zero Dengue Deaths, with a Record 14 million Global Cases Reported in 2024
MANILA, Philippines, June 16, 2025 /PRNewswire/ -- As dengue cases in 2024 double to over 14 million globally, with Asia accounting for 70% of the global burden in 2024[1], the Asia Dengue Voice and Action (ADVA) Group reinforces the call for stronger policies to strengthen dengue resilience at the 8th Asia Dengue Summit held at the Crowne Plaza Galeria Manila. Themed Toward Zero Dengue Deaths: Science, Strategy, and Solidarity, the summit held from 15 to 18 June 2025 convened over 600 participants from 22 countries, including dengue experts, global health leaders, policymakers, researchers, and advocates.
'With dengue cases persistently growing in many parts of the world including the Philippines, this summit delivers a unifying message: Dengue is preventable – and with scientific innovation, the right strategies, and strong community partnerships, achieving Zero Dengue Deaths is achievable. We want to protect lives, eliminate preventable deaths, and put a stop to this global threat,' said Dr. Ma. Rosario Z. Capeding, Organizing Chair for the 8th Asia Dengue Summit. Dr. Capeding presented an overview of dengue disease in the Philippines during the first day of the 4-day summit.
'While we can learn from the successful campaigns of our neighboring countries through this summit, we can also take this opportunity to share our own experience because we have the expertise and the commitment of our dedicated scientific community. We can share our own achievements in this battle against dengue and be considered as strong partners and powerful allies,' said Dr. Fatima I. Gimenez, Organizing Committee Co-Chair Scientific of the summit.
The Asia Dengue Summit serves not only as a platform for dialogue among policymakers and advocates, but also as a springboard for lasting partnerships and actions across sectors. ADVA, through the Asia Dengue Policy Working Group (the first under the Asia Dengue Task Force) recently released a white paper titled 'Unlocking Progress: Dengue Policies and Opportunities in Asia.'
The paper calls for stronger regional coordination and national accountability so that Asia can build more resilient and equitable systems to manage dengue and protect vulnerable populations.[1] Its country recommendation for the Philippines includes strengthening both dengue prevention through vaccination and quality care delivery. Targeted communication and global collaboration can counter misinformation and vaccine hesitancy, while expanding treatment access and ensuring guideline-based care will help save lives, especially in underserved areas.[2]
'Government can't do this alone. Every sector has a part to play,' added Dr. Gimenez. 'The health workers, advocates, the public, and media – we are all in this together. We can turn the tide on dengue.'
Empowering the next generation of dengue champions
Building on the success of its inaugural edition, the Dengue Slayers Challenge returns for a second year, continuing ADVA's partnership with Junior Achievement to empower youths in the fight against dengue.
This regional competition brings together students from Indonesia, Malaysia, Singapore, Thailand, and the Philippines, challenging them to develop innovative solutions that address the real-world complexities of dengue prevention and control.
This year, 492 teams comprising 1,812 students participated across the five countries. Participants were tasked to prototype or conceptualize technologies aimed at mosquito control or health monitoring – with a strong emphasis on digital innovation, community impact, and environment sustainability. Through this challenge, young minds not only gain exposure to international collaboration and public health issues but also take an active role in shaping the future of dengue response.
Top student teams from the five participating countries will showcase their winning solutions at the Asia Pacific Grand Finals, taking place in Manila on 17 June 2025. The event celebrates the creativity, passion, and commitment of these young innovators as they present their solutions on a regional stage.
Spotlight on DengCast: Driving Dialogue to raise dengue awareness
As part of its ongoing commitment to building advocacy and strengthening public engagement, ADVA showcased DengCast – its dedicated podcast platform to raise awareness and spark meaningful conversations around dengue.
Produced by ADVA:NexGen and available on all major platforms, DengCast features voices from across Asia, including public health experts, community leaders, and researchers, offering regional perspectives and locally driven insights. The podcast will feature dialogue with individuals who have spent their lives making a significant difference in dengue control, as well as those who are on the cutting edge of eliminating this deadly disease.
The platform continues to grow and welcomes new contributors to help broaden the conversation and inspire action at all levels of society. ADVA invites stakeholders and experts to be part of future DengCast episodes and join this regional movement to inform, engage, and empower communities in the dengue response.
For more information about the 8th Asia Dengue Summit or to access resources on dengue prevention and advocacy, visit https://www.asiadenguesummit.org/ or https://www.adva.asia/.
To read the Asia Dengue Policy Working Group White Paper, please visit https://denguetaskforce.com/publications, and follow the LinkedIn page for more updates on dengue https://www.linkedin.com/showcase/asia-dengue-pwg.
Event Partners
The co-convenors of the ADVA summit are the following, Topical Medicine and Public Health Networks, Global Dengue Plus Aedes-Transmitted Diseases Consortium, Fondation Meriuex, The International Society for Neglected Tropical Diseases, Pediatric Infectious Disease Society of the Philippines, Philippine Society for Microbiology and Infectious Diseases, Philippine Medical Association, Philippine Pediatric Society, and the Philippine College of Physicians.
About ADVA
Asia Dengue Voice and Action (ADVA) is a scientific working group dedicated to dengue vaccine advocacy in Asia, with the aim of disseminating information and making recommendations on dengue vaccine introduction strategies in Asia. The group has formulated recommendations with an ultimate aim of translating the science of dengue vaccination into messages for policy makers, general public and health care workers. For more information, visit https://www.adva.asia/.
View original content: https://www.prnewswire.com/apac/news-releases/8th-asia-dengue-summit-renews-call-to-achieve-zero-dengue-deaths-with-a-record-14-million-global-cases-reported-in-2024-302482271.html
SOURCE Asia Dengue Voice and Action
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
2 hours ago
- Fox News
Deadly bacterial outbreak infects dozens in city neighborhood as officials sound alarm
An outbreak of bacterial pneumonia has infected dozens of people in New York City, according to health officials. A total of 58 people have been diagnosed with Legionnaires' disease, a type of pneumonia caused by the bacteria Legionella. Two people have died, the NYC Health Department confirmed in an August 4 news release. The cluster of cases is concentrated in Central Harlem and bordering communities (zip codes 10027, 10030, 10035, 10037 and 10039). "Anyone in these zip codes with flu-like symptoms should contact a healthcare provider as soon as possible," said Acting Health Commissioner Dr. Michelle Morse in the health department's alert. Legionnaires' is usually found in lakes, streams and other freshwater environments. However, it can grow and spread indoors via shower heads, sink faucets, hot tubs, water features/fountains, plumbing systems and other water systems where conditions are favorable for the Legionella bacteria to grow, according to the Centers for Disease Control and Prevention (CDC). When people swallow or breathe in droplets of water that contain Legionella, they can potentially become ill with Legionnaires' disease. The disease is not typically spread from person to person, per the CDC. In the case of the New York City outbreak, the health department directed the state to perform remediation for 11 cooling towers that tested positive for the bacteria. "Legionnaires' disease can be effectively treated if diagnosed early, but New Yorkers at higher risk, like adults aged 50 and older and those who smoke or have chronic lung conditions, should be especially mindful of their symptoms and seek care as soon as symptoms begin," Morse added. Symptoms of Legionnaires' disease usually show up between two and 14 days after exposure. The condition usually causes flu-like symptoms, including cough, chills, muscle aches, fever or difficulty breathing. Some patients may also experience nausea, diarrhea and confusion, the CDC noted. "The nature of the symptoms is not necessarily what differentiates Legionella from other causes, but history of exposure from 'human-made reservoirs,' though this may be hard to discern early on in infection and/or in an outbreak," said Goodyear. Those who have any of these symptoms should seek medical attention immediately, the CDC advises. Groups at highest risk include smokers, people 50 and older, those with chronic lung disease and people who are immunocompromised, according to health officials. "Other risk factors include advancing age, cardiovascular disease, obesity and compromised immune systems," Dr. Nathan Goodyear, medical director of Brio-Medical in Arizona, previously told Fox News Digital. Around 10% of people who contract Legionnaires' disease will die from complications. Diagnosis of Legionnaires' disease is made via chest X-ray, urine test and lab analysis of a phlegm sample. Most people with the disease will recover with a course of antibiotics. In some patients, however, serious illness can lead to lung failure or death, per the CDC. Around 10% of people who contract Legionnaires' disease will die from those complications — and the mortality risk rises to 25% for those who get Legionnaires' while staying in a healthcare facility. "Treatment needs to be early and aggressive," Goodyear told Fox News Digital. "Legionella infection is an intracellular infection that requires antibiotic treatment." Antibiotics that are appropriate for Legionella infection include Levofloxacin and Azithromycin. "Therapy can be prescribed orally in healthy individuals … but intravenous antibiotics often prove to be the initial option for treatment secondary to the pathogenicity of the disease," Goodyear said. Currently, there are no vaccines for Legionnaires' disease. The best strategy to prevent infection is to reduce the growth and spread of the Legionella bacteria. For more Health articles, visit The CDC recommends that building owners and managers use a water management program to reduce the risk. To prevent serious illness from Legionnaires', Goodyear recommends that all smokers kick the habit, and also emphasizes the need to "aggressively support" chronic pulmonary disease.
Yahoo
3 hours ago
- Yahoo
CDC warns travelers about chikungunya cases in China as global infections hit 240,000
U.S. health officials are cautioning travelers about a mosquito-borne illness being transmitted in parts of Asia, South America, Africa and the Indian Ocean. Across the globe, the chikungunya virus has sparked 240,000 cases and 90 deaths in 2025, according to the European Centre for Disease Prevention and Control. The virus, which is infecting people through bites from Aedes mosquitoes, has been spreading in China's Guangdong province this summer. Health officials reported the area has seen over 7,000 confirmed cases since June. The U.S. Centers for Disease Control and Prevention (CDC) this month issued a travel notice for the Guangdon province in China, encouraging travelers to practice enhanced precautions. The agency issued the same notices for other countries where outbreaks have been reported, including Bolivia, Kenya, Madagascar, Mauritius, Mayotte, Réunion, Somalia and Sri Lanka. The CDC is also asking U.S. residents to exercise caution when visiting the following countries, which have not yet reported an outbreak but are at elevated risk of exposure: Brazil, Colombia, Mexico, India, Pakistan, Philippines, Thailand and Nigeria. According to the World Health Organization (WHO), 5.6 billion people are at risk of arboviral diseases such as chikungunya. Other widespread arboviruses impacting humans include dengue, Zika and yellow fever. What are the symptoms of chikungunya? Symptoms of the disease include fever, joint pain and swelling, headache, muscle pain and rash, according to the CDC. How long does infection last? The illness typically lasts between two to 12 days after infection. Some patients can experience extreme symptoms and the virus can be fatal. Elderly people, newborns and individuals with underlying medical conditions are at higher risk of medical intervention. Severe complications, including cardiovascular, neurological and multiorgan involvement, may require intensive medical care, according to the WHO. However, more than half of patients will experience symptoms commonly associated with a fever. What treatments are available? There are no known antiviral treatments for the illness. Medications can be used to manage pain and fever. Two chikungunya vaccines have received regulatory approval but are not widely available. In May, federal officials recommended pausing a vaccine in the United States after reports of serious adverse events. The illness was first discovered in Tanzania in 1952, with outbreaks being reported in Africa and Asia, according to the WHO. Since then, the virus has been transmitted to 119 countries. Last year, more than 620,000 and 213 deaths were reported globally, according to the European Centre for Disease Prevention and Control. In what was then dubbed the largest documented outbreak of chikungunya, an estimated several hundred thousand people were affected by "explosive" outbreaks of the virus in the Indian Ocean islands and India, according to a 2008 study. It's estimated that about 60 percent of regional populations were exposed. CDC issues travel notice for Americans The CDC issued a travel warning on Friday, Aug. 1, advising U.S. residents to take enhanced precautions when traveling to China. Most of the country's cases have been reported in the city of Foshan. Last month, Chinese officials held a national conference to discuss treatments for and prevention of the illness. Authorities agreed to continue monitoring the situation and issue early warnings through multiple channels to prevent further spreading, according to China's National Health Commission. Michelle Del Rey is a trending news reporter at USA TODAY. Contact her at mdelrey@ This article originally appeared on USA TODAY: Chikungunya virus cases reported in China prompt CDC travel notice Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
JAMA Surgery Study Confirms Diagnostic Value of Cizzle Bio's DEX-G2 Blood Test For Early Detection of Gastric Cancer
SAN ANTONIO, Aug. 5, 2025 /PRNewswire/ -- A groundbreaking multicenter clinical study published on July 30 in JAMA Surgery confirms the powerful diagnostic performance of the Destinex assay, a novel liquid biopsy that serves as the foundation for Cizzle Bio's DEX-G2 blood-based assay for early detection of gastric cancer—one of the world's deadliest malignancies. The study's findings validate the clinical utility of DEX-G2 as a minimally invasive, clinically actionable tool to detect gastric cancer at its earliest and most treatable stages, when timely intervention can significantly improve outcomes and save lives. The DESTINEX study, conducted at leading cancer centers in Japan and South Korea, evaluated a signature panel of microRNAs derived from exosomes and cell-free serum. The study analyzed 809 serum specimens from 480 participants, including patients with gastric cancer and matched controls. Using machine learning to refine and validate the assay, researchers demonstrated exceptional diagnostic accuracy for early-stage gastric cancer. The study was led by Ajay Goel, Ph.D., AGAF, an internationally recognized leader in cancer biomarker research and the developer of the Destinex assay. Goel also serves as scientific advisor to Cizzle Bio and is chair of the Department of Diagnostics and Experimental Therapeutics at City of Hope Comprehensive Cancer Center, where he led the development of the Destinex assay into the DEX-G2 blood test that Cizzle Bio is now advancing for near-term commercial launch. "The publication of this study in JAMA Surgery is a critical milestone, not only for our scientific team but also for the future of early gastric cancer detection," said Goel. "By combining the sensitivity of cell-free microRNAs with the specificity of exosomal markers, Destinex—and now DEX-G2—offers a minimally invasive, accessible, and highly accurate method for detecting gastric cancer at a stage when outcomes can be dramatically improved." In the study, the Destinex assay achieved an area under the curve (AUC) of 96.8% in the validation cohort, with a sensitivity of 95.0% for detecting early-stage (pT1) gastric cancer. These findings underscore the assay's strength as a minimally invasive tool for identifying gastric cancer early when it is most curable. The assay achieved high sensitivity and specificity in distinguishing individuals with gastric cancer from those without the disease, confirming its potential not only as a minimally invasive screening tool but also to significantly improve patient outcomes through earlier detection and intervention. A Pressing Clinical Need Gastric cancer is the third leading cause of cancer-related deaths worldwide, mainly due to delayed diagnosis. Globally, more than 60% of gastric cancer cases are diagnosed at advanced stages, when curative treatment is no longer an option and prognosis is poor. Endoscopic screening has helped reduce mortality in high-incidence countries such as Japan and Korea, but its cost, invasiveness, and limited availability make it impractical for widespread use in low-incidence regions. Minimally invasive blood-based tests like DEX-G2 have the potential to fill this gap. The Destinex assay, the scientific basis of DEX-G2, demonstrated outstanding sensitivity and specificity for detecting early-stage (T1) gastric cancer, and its diagnostic performance remained robust across tumor stages and patient subgroups. The study also showed a significant drop in biomarker levels after surgical tumor removal, confirming the assay's tumor specificity. Read the full JAMA Surgery study here: "This study reinforces the scientific credibility and clinical utility of the technology behind DEX-G2," said Bill Behnke, CEO of Cizzle Bio. "We are proud to advance this innovation into clinical practice, where it has the potential to make earlier detection a reality for patients who currently have few options for early detection." From Discovery to Clinical Application Cizzle Bio is advancing its DEX-G2 test, based on the Destinex assay, for near-term commercial deployment in CLIA-certified laboratories. It is intended to support clinicians in detecting gastric cancer earlier, particularly in primary care and gastroenterology settings where endoscopy may not be accessible or practical. The company holds a worldwide exclusive license for DEX-G2 and is actively pursuing commercialization in both U.S. and global markets, with a focus on reaching populations where gastric cancer is often diagnosed too late for curative treatment. About Cizzle Bio Cizzle Bio is a Texas-based biotechnology company dedicated to revolutionizing cancer diagnostics by advancing biomarker-based blood tests, starting with early detection of lung and gastric cancers. Our goal is to empower patients, equip clinicians, and improve outcomes through innovation, compassion, and life-saving solutions. We hold exclusive licensing rights for our groundbreaking CIZ1B biomarker test in the United States, Canada, and the Caribbean and a worldwide exclusive license for our DEX-G2 biomarker gastric cancer test. Cizzle Bio is commercializing both tests for U.S. clinical Media Contact: Yolanda Heibergeryolanda@ View original content to download multimedia: SOURCE Cizzle Bio
